Trial Profile

A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Mar 2022 Results published in the Journal of the American College of Cardiology
08 Apr 2020 Results (n=32) assessing gene expression profile of circulating monocytes of healthy individuals and CVD patients, both with elevated Lp(a) in two studies (AKCEA-APO(a)-LRx study (NCT03070782) and the ANITSCHKOW study (NCT02729025)), published in the European Heart Journal.
02 Jan 2020 Results published in Akcea Therapeutics media release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com